Last Notes
They ran out of tolerance for broken Nostr clients /j
Or, be like @nprofile…3wq8 and build something worse with your VC money, then complain about Nostr and call everyone losers, then not deliver a product anyone wants to use, and then go back to Xitter and act like you deserve a prize.
”Nice icebergs youse got there. Be a real shame if sumthin’ was to happen to ‘em.” — Don Trump Corleone
https://blossom.primal.net/e61c79346272dcc6912a315e22296c7adfbec31bed9bee1d25b263aaeab60250.gif
I might murder you for my own amusement, but I won't steal your Bitcoin.
https://npub1un5y07dnu20fxzelq5scweuz37xa6kkpwl66634xv9h49ewr04kswpevsy.blossom.band/c6266d9d45c00c5edd355775f45900e62caea001011caced7f78e971a2c83082.jpg
https://blossom.ditto.pub/f1b97dd0a0210255f8a93911b28d32d3c4a36b966044b1d97c962fa01877e83b.gif
#Merica #USA
CC: @nprofile…3zjm , @nprofile…qpk8 , @nprofile…8g48
#nevent1q…90k9
When diesel at 20 dollars per gallon? Maybe should start a polymarket or something
GN https://haven.dergigi.com/97ae6dbbf96e5e11e4091f372bf7294f05ea8fd0bd18c4e81bcdf3d5710d7b59.jpg
I'm pretty sure it was the CIA that spun this narrative that transparency is more important than privacy.
None of what you just said even remotely applies to Monero, which is what we're talking about here.
I go to places I hate too. Purely not to have fun or enjoy myself 😂
@npub1jcj…mtwx
https://image.nostr.build/9745776ab05e18c84adf4de87b6c31eec3e49590291c6a42ce4423f2146ddade.jpg
https://image.nostr.build/3a7781313d7d378de63f96b9347b15554b4a4204eaf461296a439c35bc061548.jpg
https://image.nostr.build/fc350c7a3f83fbfe14857c13414a52e8e7b1cbf49d42d455df621da532e575b6.jpg
https://image.nostr.build/131ca4ed24ac7a6fe2ee54b379bbed8a0c565dda9e6ef9dc09c89f33fcf5feb9.jpg
https://image.nostr.build/f63170999839fa958f07f607b484026ad40c176f1b76a1e8c967defb17cc2534.jpg
Nothing gives me more confidence in my choices in life than to be considered not “worth anything” to that dolt. Good riddance. 😂
Tell me you don’t understand nostr, without telling me 🤣
#nevent1q…2sqs
Day 13: Final daily update testing a Monero payment target on my profile. Totals below.
The Monero tips/xaps slowed down the last few days, but this was a fun and eye opening experiment. Monero xaps were generally larger in size but fewer in quantity/frequency, whereas Bitcoin zaps were much smaller in size but greater in quantity/frequency.
A handful of fat zaps narrowed the difference between the two (shoutout to @nprofile…msju for a few of those), but the Monero gang still beat out the bitcoiners in terms of total value sent.
Personally I find that larger tips feel more impactful, even though they’re fewer in number. Both are appreciated, but one or two fat zaps just makes a much different impression. Whether the tips were bitcoin or monero made no difference to me in terms of impact, as everything will get converted into my currency of choice. Both felt equally valuable to receive.
Fun experiment. The payment target will stay on my profile. I wish more client apps supported them.
Day 13 totals:
- 21533 sats, ($17.48, 13 zaps)
- 0 XMR
Running totals:
- 88025 sats ($71.47)
- Avg. zap: 391 sats (32¢)
- 0.1835652 XMR ($105.82)
- Avg. xap: 0.0122 XMR ($7.03)
#nevent1q…je0q
Wait, wot?
Did somebody sign me up to something while I was in the operating theatre? 👀
What, with war coming!
Not a chance 😂
#nevent1q…kx8p
Lol then my instinct to quit was on point lol
I guess I'm the kind 1 Sisyphus.
It became more serious than I care to admit, but I'm doing OK now.
https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcSrk4vt30xdM0KBOdphaZEtYsr21o_GQ0ry_7T_0Od88tmhiBa4jvRUxSg&s=10
Gosh.. just sent you a new version of this as a comment on one of your note 🤣😂🫂
He can brag about it to all 7 people on Pubeky now.
Doesn't it have to be a meme to be classified as stealing? 😂
My wife, the podiatrist, says I've got a couple of feet 😂
I can hear the overmind regardless
Refer to this meme
Take the L @npub1m2u…y2gl
https://node.blossom.band/f7455b7b1558c8fe91226534ab95f3fa8736a48db8a8b64543c9e9a3cdae3689.jpg
Satoshi said he was moving on to other things. Many of the Monero devs are anonymous. I sometimes wonder if he's been quietly contributing under a different nym.
Heyyyy Mehple. That sounds amazing. Thank you and same to you brother
https://i.nostr.build/OktHnkBlvxInx64c.gif
Hey try having your appendix out and then see how you function 😂
https://i.nostr.build/VCfBZMqFSnThIoAlI7i4JW.jpg
Damn, that joke missed by a country mile 🥹
That post did numbers on Xitter, LMAO.
Keep going. It's like entering developer mode on your android phone. You know you're almost there when your eye goes red.
He didn’t delete anything. He just rage quit and threw his toys out of the crib because he couldn’t accept that nobody gives a shit about him or his products.
https://blossom.jumble.social/6a1e5ff38e316b01dfa5ec481a4ce1e595b3e2847889620336d819076e7d4088.jpg
Perhaps we should rename it to stalking 😂
I love how he had to announce it too.
# Comparing mitragynine to opioids
Mitragynine has opioid activity—it is not pharmacologically separate from opioids. It is the main alkaloid in kratom and acts on the same μ-opioid receptor (“mu receptor”) targeted by morphine and other opioid painkillers. The useful comparison is therefore between mitragynine’s atypical opioid pharmacology and that of conventional opioid drugs, rather than “kratom compound versus opioid.”
The main functional differences concern how strongly it activates that receptor, what your body converts it into, and which other biological systems it affects.
1. It activates opioid receptors differently
Drugs such as morphine produce substantial μ-receptor activation, which contributes to both pain relief and potentially dangerous suppression of breathing. Mitragynine has comparatively low intrinsic efficacy at the human μ receptor: in laboratory studies, it behaves as a partial agonist, activating the receptor less strongly than a full agonist can in the same experimental system.
Think of receptor binding and receptor activation as two separate properties. A drug can attach to a receptor without turning its activity up very much. Consequently, “partial agonist” does not simply mean “a smaller dose of a strong opioid.” It describes a different ability to activate the receptor. The resulting effects still depend on the tissue, dose, and other compounds present.
This distinction is not unique to mitragynine. Buprenorphine is also a partial μ-opioid agonist, so not all conventional opioid medications belong on the “full agonist” side of the comparison. Sharing partial agonism does not make mitragynine and buprenorphine interchangeable.
2. Its metabolite is an important part of the story
Mitragynine can be converted into 7-hydroxymitragynine, commonly abbreviated 7-OH, through metabolism involving the enzyme CYP3A4. That metabolite has substantially greater opioid-receptor potency than mitragynine itself. Researchers demonstrated this conversion in human liver preparations and found that the metabolite accounted for much of mitragynine’s opioid-mediated pain relief in mice. The exact contribution to effects in humans is less firmly established.
This means that what mitragynine does in an isolated receptor experiment is not necessarily what happens after someone swallows it. The parent compound and the metabolites formed afterward can have different effects.
It also means that ordinary kratom leaf, purified mitragynine, and products enriched with 7-OH should not be treated as equivalent. Natural leaf contains relatively little 7-OH; concentrated products can expose someone directly to much larger amounts of this more potent compound.
3. Its effects are not exclusively opioid effects
Mitragynine’s pharmacology extends beyond μ-opioid receptors. For example, laboratory and animal studies have investigated interactions with alpha-2 adrenergic receptors, part of the system that responds to norepinephrine. However, receptor binding does not automatically establish a meaningful effect in humans, and the experimental findings are not simple enough to describe mitragynine as merely “an opioid plus a stimulant.”
There is another distinction here: kratom is a mixture, whereas mitragynine is one molecule. Kratom contains numerous other alkaloids, so an effect reported after taking kratom cannot automatically be attributed to mitragynine alone.
4. Breathing suppression may differ—but “it cannot suppress breathing” is wrong
There is experimental evidence that mitragynine’s respiratory effects differ considerably from those of morphine. In a 2025 rat study, intravenously administered mitragynine increased breathing frequency rather than suppressing it, whereas 7-OH and morphine both caused significant respiratory depression. Naloxone reversed the breathing suppression caused by 7-OH and morphine. High-dose mitragynine nevertheless caused seizure-like toxicity in some animals. These findings do not establish a safe dose or a guaranteed respiratory ceiling for oral use in humans.
You may encounter an explanation that mitragynine favors G-protein signaling over β-arrestin recruitment, two processes associated with opioid-receptor activation. Laboratory studies support this distinctive signaling profile. But the popular conclusion—“it avoids β-arrestin, therefore it cannot cause an opioid overdose”—goes beyond the evidence.
Broader opioid research suggests that low receptor-activating efficacy, not necessarily signaling bias alone, may explain some improved safety profiles. The relative contributions remain debated; neither characteristic is a guarantee against respiratory depression.
5. Dependence and other opioid-type effects remain possible
Kratom products can produce nausea, constipation, sedation, tolerance, physical dependence, and withdrawal. Their atypical pharmacology does not eliminate these possibilities. Human evidence also does not establish a reliable, universal conversion between a quantity of mitragynine and an equivalent dose of a prescription opioid. Kratom and its alkaloids are not FDA-approved treatments for pain or opioid withdrawal.
Bottom line: Mitragynine is best understood as an atypical opioid-active compound with relatively low μ-receptor efficacy, additional non-opioid actions, and a more potent opioid metabolite. Those differences can meaningfully change its effects compared with morphine—but they do not make it opioid-free, non-dependence-forming, or incapable of serious toxicity. Mitragynine and concentrated 7-OH are especially important not to conflate.
One can simply not delete the Nostr. 😂
Many protocols depend on this. Even Nostr would be half-broken
Finally a marketing campaign
https://blossom.jumble.social/248ad1472207268bcd598bfd0fbc9c806d0be81006d0d33bd9982da11e482c54.jpg